Complement factor H autoantibodies are associated with early stage NSCLC

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3226-3231

  Amornsiripanitch, Nita ^a   Hong, Shaolin ^a   Campa, Michael J ^a   Frank, Michael M ^a   Gottlin, Elizabeth B ^a   Patz Jr , Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN MICROARRAY; SMOKING;

AGED; AUTOANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; COMPLEMENT FACTOR H; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 77953717551     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0321     Document Type: Article

References (26)

1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. (Pubitemid 47171780)
2. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705. (Pubitemid 47357521)
3. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009;58:1535-44.
4. Hoagland LF IV, Campa MJ, Gottlin EB, Herndon JE II, Patz EF, Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 2007;110:2260-8.
5. Sayegh R, Awwad JT, Maxwell C, Lessey B, Isaacson K. Alpha 2-macroglobulin production by the human endometrium. J Clin Endocrinol Metab 1995;80:1021-6.
6. Dean RB, Dixon WJ. Simplified statistics for small numbers of observations. Anal Chem 1951;23:636-8.
7. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37. (Pubitemid 46143500)
8. Birchard KR, Hoang JK, Herndon JE, Jr., Patz EF, Jr. Early changes in tumor size in patients treated for advanced stage non-small cell lung cancer do not correlate with survival. Cancer 2009;115:581-6.
9. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. Febs J 2009;276:6880-904.
10. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3. (Pubitemid 26014201)
11. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005;4:1123-33. (Pubitemid 41208670)
12. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007;6:1115-22. (Pubitemid 47099223)
13. Salazar L, Disis ML. Antibodies to human tumor oncoproteins in cancer patients. In: Stauss H, Kawakami Y, Parmiani G, editors. Tumor antigens recognized by T cells and antibodies. New York: Taylor and Francis; 2003, p. 172-90.
14. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007;46:316-23. (Pubitemid 46625032)
15. Kurtenkov O, Klaamas K, Rittenhouse-Olson K, et al. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Exp Oncol 2005;27:136-40. (Pubitemid 41025736)
16. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998;46:245-52.
17. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83. (Pubitemid 30078538)
18. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-6.
19. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
20. Finn OJ. Human tumor immunology at the molecular divide. J Immunol 2007;178:2615-6.
21. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9.
22. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41:355-67. (Pubitemid 38639887)
23. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998;113:173-82. (Pubitemid 28352834)
24. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 2007;178:5991-8. (Pubitemid 46674397)
25. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000;164:6075-81. (Pubitemid 30389858)
26. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-63. (Pubitemid 41725154)